Progesterone prescription in pregnancy: revisiting rationality
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20251241Keywords:
Dosage, IHCP, Liver, Preparations, ProgesteroneAbstract
Background: Progesterone is widely used in pregnancy for conditions like luteal phase defects and preterm labor prevention. However, irrational use, especially prolonged or with multiple formulations, raises concerns about liver dysfunction and intrahepatic cholestasis of pregnancy (IHCP). This study aimed to assess the impact of progesterone use on liver function tests (LFTs) and IHCP incidence based on duration and type of therapy.
Methods: A prospective study of 150 antenatal women categorized into three groups: no progesterone (Group A), progesterone until 16 weeks (Group B), and until 32 weeks (Group C). Liver enzyme levels were measured at baseline, mid, and late pregnancy. IHCP was diagnosed with bile acid levels >20 mmol/l.
Results: IHCP incidence was significantly higher in Group C (28%) compared to Group A (4%) and Group B (12%) (p<0.001). There was significant reversible rise of liver enzymes in group B which normalised after the stoppage of progesterone while in group C, liver enzymes remain persistently elevated.
Conclusions: Prolonged and multiple progesterone formulations led to persistent liver enzyme elevation but these changes are transient and go away quickly when the dose is discontinued or modified. Rational prescribing based on clear indications and appropriate formulations is essential for safe outcomes. Choosing the right patients is the main factor that determines how effective progesterone supplements are.
Metrics
References
Romero R, Conde-Agudelo A, Da Fonseca E, O'Brien JM, Cetingoz E, Creasy GW, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol. 2018 Feb;218(2):161-80. DOI: https://doi.org/10.1016/j.ajog.2017.11.576
Maybin JA, Critchley HO. Medical management of heavy menstrual bleeding. Womens Health (Lond). 2016;12(1):27-34. DOI: https://doi.org/10.2217/whe.15.100
Maiskar V, Surve S. Early Onset Intrahepatic Cholestasis of Pregnancy: Is Progesterone Supplementation to be Blamed For? J Obstet Gynaecol India. 2019;69(2):192-3. DOI: https://doi.org/10.1007/s13224-018-1174-9
Kazemi Aski S, Sharami SH, KabodMehri R, Rahnemaei FA, Milani F, Sabetghadam S. Association between the duration of progesterone supplementation treatment and premature neonates outcomes: A retrospective cohort study. Health Sci Rep. 2023;6(11):e1721. DOI: https://doi.org/10.1002/hsr2.1721
Alizadeh F, Mahmoudinia M, Mirteimoori M, Pourali L, Niroumand S. Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth. BMC Pregnancy Childbirth. 2022;22(1):167. DOI: https://doi.org/10.1186/s12884-022-04509-1
Ghosh S, Chaudhuri S. Intra-hepatic Cholestasis of Pregnancy: A Comprehensive Review. Indian J Dermatol. 2013;58(4):327. DOI: https://doi.org/10.4103/0019-5154.113971
Liu L, Zhou H, Hu J, Sun X, Liu D, Huang G. Association between duration of progesterone supplementation and clinical outcomes in artificial frozen-thawed embryo transfer cycles. Front Endocrinol (Lausanne). 2023;14:1193826. DOI: https://doi.org/10.3389/fendo.2023.1193826
Qureshi S, Alvi A, Chachar A, Sohaib M, Ali S, Abdullah M. Maternal and fetal outcomes in women receiving ursodeoxycholic acid (UDCA) as treatment for intrahepatic cholestasis of pregnancy (ICP), a single center experience: are we doing enough? Biol Clin Sci Res J. 2023;2023(1):559. DOI: https://doi.org/10.54112/bcsrj.v2023i1.559
Downloads
Published
How to Cite
Issue
Section
